Serenium

Description

• Serenium is reducing chronic diseases by the early identification and treatment of sleep apnea with an initial focus on the USA and China. People with sleep apnea are 200 % to 500 % more likely to have these chronic diseases (diabetes, hypertension, depression). A clinically validated, easy-to-use and economical (< $ 50) screening solution will be a valuable offering to the 500,000,000 people at risk for sleep apnea in just the USA and China markets, and will better penetrate the 80 - 95 % of the sleep apnea market that is currently undiagnosed. Our Cloud Apnea System using a proprietary neural network algorithm, is showing about a 90% agreement with the gold standard test (polysomnography) in a 4,000 children study that will become a landmark clinical publication in mid 2017. This innovative screening solution will be launched in mid 2017 in the USA & China. Our Cloud Apnea System for adults will be tested by the end of 2017. Serenium has a proprietary Urine Biomarkers test for the early identification of sleep apnea, showing a 97.7% agreement with polysomnography, which will be commercialized in 2018. Our screening solutions will also secure a significant Big Data repository, which will create additional product and commercial opportunities in the future. We have advanced the right resources to make Serenium a success (strong team, IP & trade secrets, products) and will bring these innovative solutions to the global health markets. Please contact us for more information (Info@SereniumScreen.com).
• 

  Headquarters:4250 Executive Square , San Diego, California, United States

  More
• 

  Phone Number: +1 650-224-6446

• 

  Website: https://www.serenium-inc.com

• 

  Employees:3

• 

  Revenue:$0 - 1M

• 

  Legal Name:Serenium

• Serenium's Social Media

  
• Is this data correct?

• |  NAICS Code: 541713  |

  Show More